ArticleScientific data2026
A Serum and Urine Metabolomics Dataset of TCM Syndromes in Cholelithiasis.
Article in Scientific data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The present study investigated the distinct metabolic profiles of two primary traditional Chinese medicine (TCM) syndromes in patients with cholelithiasis-liver Qi stagnation (LQS) and liver-gallbladder damp-heat (LGDH). By integrating untargeted and targeted metabolomics, we aimed to identify objective serum and urine biomarkers for syndrome differentiation and to elucidate their underlying biological basis. In total, 91 participants, comprising 33 healthy controls (HCs), 30 cholelithiasis patients with LQS syndrome, and 28 cholelithiasis patients with LGDH syndrome, were enrolled. Untargeted analysis of serum and urine samples quantified 602 and 636 metabolites, respectively. To strengthen the robustness of the dataset, complementary targeted metabolomics was conducted as an orthogonal validation step, providing reliable quantification for 210 serum and 204 urinary. The present findings provide molecular insights into the TCM principle of syndrome differentiation (Bian Zheng Lun Zhi). The identified biomarker panel may offer a basis for developing objective tools for the stratification of cholelithiasis syndromes and may support future efforts towards personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.